Oct 6, 2018 T-CALM Phase 2 clinical study results offer hope for essential tremor patients T-CALM Phase 2 clinical study results offer hope for essential tremor patientsCavion, Inc., a leading clinical stage biotechnology company committed to developing novel therapeutics for people with neurological diseases, today ... read morePublished on 2018-10-06